Thermo Fisher Expands Biologics and Steriles Manufacturing Capabilities in China

Published on: 

Thermo Fisher Scientific’s new facility in Hangzhou, China, is designed to boost biologics and sterile development and manufacturing capabilities in the Asia-Pacific region.

Thermo Fisher Scientific announced the opening of a new facility in Hangzhou, China, on Dec. 8, 2022. The 80,000 m² current good manufacturing practices (CGMP) facility is designed to boost biologics and sterile development and manufacturing capabilities in China and the greater Asia-Pacific region.

According to a company press release, the facility will offer integrated clinical and commercial drug substance and drug product capabilities. This includes process development, cell line development, biologics drug substance manufacturing, and sterile fill-finish. The company also plans to feature commercial packaging and labeling capabilities in the future as well as expand its on-site bioreactors capacity from 2000 L to 5000 L.

"Hangzhou is a strategic addition to our global pharma services network and the latest example of our commitment to meeting customer demands globally,” said Mike Shafer, senior vice-president and president, Pharma Services, Thermo Fisher Scientific, in the release. “We continue to invest in capabilities to support the manufacturing needs of our customers, enabling them to serve more patients throughout the world.”


“Thermo Fisher has been in China for 40 years, serving this market through its bioproduction, clinical research, and pharma services businesses,” said Hann Pang, president, Thermo Fisher China, in the release. “Committed to our ‘in China, for China’ localization strategy, we are enhancing our workflow capabilities to fully support pharmaceutical and biotechnology companies in China and worldwide in helping more local innovations go global.”

Source: Thermo Fisher Scientific